IMIDomics has entered an exclusive agreement to license TNAX Biopharma’s drug candidate, IMB1001, to potentially treat immune-mediated inflammatory diseases (IMIDs).
As per the deal, IMIDomics will gain access to global rights for the development, production, marketing and sub-licensing of IMB1001 from TNAX.
A humanised antibody that acts on CD226, IMB1001 is currently in the preclinical development stage.
The agreement comprises all patents, rights and information linked to the drug candidate, including its usage in humans as well as animals.
The companies did not divulge the financial terms of the deal but it is said to comprise upfront, milestone and royalty payments.
IMIDomics chief development officer H Daniel Perez said: “In licensing this promising new drug candidate, we are demonstrating our commitment to applying our proprietary Clinical Discovery Engine in service of discovering and developing impactful medicines for IMID patients and underscoring our confidence in the potential of this therapeutic candidate.
“The licence of IMB1001 from TNAX accelerated our efforts to translate our scientific discoveries into meaningful therapeutic options.”
IMIDomics detected the CD226 target by leveraging its data-powered platform, Clinical Discovery Engine, to explore IMIDs’ underlying processes.
A transmembrane glycoprotein, CD226 has a key role in the immune response.
IMB1001 is said to possess wider applicability across various ailments, especially for patients who are unresponsive or intolerant to the existing standard of care treatments.
IMIDomics will expedite the development of this antibody to exploit its potential across various IMIDs.